OptimizeRx (OPRX) Scheduled to Post Quarterly Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX) will be announcing its earnings results after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of $0.03 per share for the quarter.

Shares of NASDAQ:OPRX opened at $14.97 on Wednesday. The business has a fifty day moving average of $15.28. The company has a market cap of $188.56 million, a price-to-earnings ratio of 299.40, a price-to-earnings-growth ratio of 1.76 and a beta of 0.51. OptimizeRx has a one year low of $8.92 and a one year high of $18.39. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.03.

Separately, Zacks Investment Research lowered shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. OptimizeRx currently has a consensus rating of “Buy” and an average price target of $19.00.

In other news, major shareholder Awm Investment Company, Inc. sold 82,126 shares of the stock in a transaction on Monday, May 13th. The shares were sold at an average price of $13.64, for a total value of $1,120,198.64. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

About OptimizeRx

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Featured Article: What is Cost of Capital?

Earnings History for OptimizeRx (NASDAQ:OPRX)

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.